A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and antiviral activity of orally administered study drug regimens in hospitalized or non-hospitalized infants and children aged 28 days to 24 months infected with RSV (respiratory syncytial virus).
Explore related content and topics
Page
Respiratory
Our expertise allows us to navigate the complexities of respiratory research, providing effective solutions across every facet of respiratory drug…
Blog
Ask the Experts: What is the Current Clinical Development for Respiratory Conditions?
COVID-19 is a disease that heavily affects the respiratory systems of those that contract the disease. Inspired by Respiratory Care Week, we must pay…
Blog
Ask the Experts: What Dangers Does the COVID-19 Pandemic Bring to Respiratory Disease Patients?
Over the last eight months, the world has become familiar with how COVID-19 affects the human body and spreads. COVID-19 is a respiratory disease…